SML0936
特立氟胺
≥98% (HPLC), anti-inflammatory immunomodulator, powder
别名:
(Z)-2-氰基-3-羟基-N- [4-（三氟甲基）苯基]-2-丁烯酰胺, A 1726, A77-1726, A771726, HMR 1726, N-（4-三氟甲基苯基）-2-氰基-3-羟基克罗胺, SU 20, 氟酰胺
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
产品名称
特立氟胺, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear (warmed)
storage temp.
−20°C
InChI
1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
InChI key
UTNUDOFZCWSZMS-YFHOEESVSA-N
Application
特立氟胺是一种二氢乳清酸脱氢酶 (DHODH) 抑制剂。
Biochem/physiol Actions
特立氟胺是一种可口服的抗炎免疫调节剂。
特立氟胺是一种可口服的抗炎免疫调节剂。阻断二氢乳清酸脱氢酶的活性，阻止嘧啶合成及 T、B 细胞增殖和功能。特立氟胺用于治疗风湿性关节炎，最近被批准用于多发性硬化症。
Still not finding the right product?
Explore all of our products under 特立氟胺
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia.
Sykes D B, et al.
Cell, 167(1), 171-186 (2016)
Deepti Mathur et al.
Cancer discovery, 7(4), 380-390 (2017-03-04)
Metabolic changes induced by oncogenic drivers of cancer contribute to tumor growth and are attractive targets for cancer treatment. Here, we found that increased growth of
Mieradilijiang Abudupataer et al.
eLife, 10 (2021-09-07)
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular disease in general population and is frequently associated with the development of thoracic aortic aneurysm (TAA). There is no effective strategy to intervene with TAA progression due to an incomplete
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0936-10MG | 04061837107337 |
| SML0936-50MG | 04061837107344 |